SlideShare a Scribd company logo
1 of 29
Antidepressants
Dr. S. Parasuraman M.Pharm., Ph.D.,
Senior Lecturer, Faculty of Pharmacy,
AIMST University,
Bedong 08100, Malaysia.
Depression
• Major depression and mania are two extremes of
affective disorders which refer to a pathological change
in mood state.
• The symptoms of depression are intense feelings of
sadness, hopelessness, and despair as well as the
inability to experience pleasure in usual activities,
changes in sleep patterns and appetite, loss of energy,
and suicidal thoughts. Mania is characterized by the
opposite behavior: enthusiasm, rapid thought and
speech patterns, extreme self-confidence, and impaired
judgment.
Classification of anti-depresent
• Reversible inhibitors of MAO-A (RIMAs): Moclobemide,
Clorgyline
• Tricyclic antidepressants (TCAs):
– NA + 5-HT reuptake inhibitors: Imipramine, Amitriptyline,
Trimipramine, Doxepin, Dothiepin, Clomipramine
– Predominantly NA reuptake inhibitors: Desipramine,
Nortriptyline, Amoxapine, Reboxetine
• Selective serotonin reuptake inhibitors (SSRis): Fluoxetine,
Fluvoxamine, Paroxetine, Sertraline, Citalopram, Escitalopram
• Atypical antidepressants: Trazodone, Mianserin, Mirtazapine,
Venlafaxine, Duloxetine, Tianeptine, Amineptine, Bupropion
• 5-HT2Antagonists: trazodone and nefazodone
• AC, adenylyl cyclase;
• 5-HT, serotonin;
• CREB, cAMP response element-
binding (protein);
• DAG, diacyl glycerol;
• IP3, inositol trisphosphate;
• MAO, monoamine oxidase;
• NET, norepinephrine
transporter;
• PKC, protein kinase C;
• PLC, phospholipase
Depression
Hypothesis of major depression
• Depression appears to be associated with changes in
serotonin or norepinephrine signaling in the brain (or
both) with significant downstream effects.
• Most antidepressants cause changes in amine signaling.
MAO inhibitors
• MAO is a mitochondrial enzyme involved in the oxidative
deamination of biogenic amines (Adr, NA, DA, 5-HT). Two
isoenzyme forms of MAO have been identified.
• Dopamine is degraded equally by both isoenzymes.
• MOA inhibitors inhibits the metabolism of biological amines
to cause disproportionate elevation of mood.
MOA isoenzymes Active against Inhibited by
MAO-A 5-HT and NA Clorgyline,
Moclobemide
MAO-B Phenylethylamine Selegiline
MAO inhibitors
• The nonselective MAO inhibitors causes
– elevate the mood in depressed patients
– progress to hypomania and mania
– excitement and hypomania may be produced in nondepressed
individuals
• The drugs themselves stay in the body for relatively short
periods, but their effects last for 2-3 weeks after
discontinuation.
• MOA inhibitors are 'hit and run' drugs-return of MAO
activity depends on synthesis of fresh enzyme; tissue
monoamine levels remain elevated long after the drug has
been largely eliminated.
MAO inhibitors
• Interactions: MAO inhibitors inhibits a number of other
enzymes as well, and interact with many food constituents
and drugs.
– Cheese reaction: MAO inhibiters indirectly acting sympathomimetic
amines escape degradation in intestinal wall and liver  reaching
into systemic circulation they displace large amounts of NA from
transmitter loaded adrenergic nerve endings  hypertensive crisis,
cerebrovascular accidents. Alpha blockers (e.g.: phentolamine,
prazosin) or chlorpromazine can be used for treatment of chees
reaction.
– Cold and cough remedies: Cough syrup contains ephedrine or
other sympathomimetics  cause hypertensive reaction.
– Reserpine, guanethidine, tricyclic antidepressants: Excitement,
rice in BP and body temperature can occur when given these drugs
to patient on MOA inhibitor (due to NA release or uptake blocking
action).
MAO inhibitors
– Levodopa: Excitement and hypertension, due to increase in
biological half life of DA and NA.
– Antiparkinsonian anticholinergics: Hallucinations and symptoms
similar to those of atropine poisoning occur.
– Barbiturates, alcohol, opioids, antihistamines: respiration may fail.
– Pethidine: High fever, sweating, excitation, delirium, convulsions,
and severe respiratory depression may occur.
Reversible inhibitors of MAO-A
Moclobemide
• It is reversible and selective MAO-A inhibitor with short duration of
action and full MAO activity is restored within 1-2 days of stopping the
drug.
• Its effective antidepressant, comparable to TCAs.
• It lacks the anticholinergic, sedative, cognitive, psychomotor and
cardiovascular adverse effects of typical TCAs and is safer in overdose.
• ADR: nausea, dizziness, headache, insomnia, rarely excitement and
liver damage.
• Use: Alternative for TCAs for mild to moderate depression and social
phobia.
• Dose: 150 mg; BD or TID (Max 600 mg/ kg/ day)
TRICYCLIC ANTIDEPRESSANTS (TCAs)
Imipramine
• It is an analogue of CPZ and found during clinical trails to selectively
benefit depressed but not agitated psychotics.
• MOA:
– TCAs block norepinephrine and serotonin reuptake into the neuron.
– Inhibition of neurotransmitter reuptake: TCAs is potent inhibitors of the
neuronal reuptake of norepinephrine and serotonin into presynaptic
nerve terminals. At therapeutic concentrations, they do not block
dopamine transporters. TCAs cause increased concentrations of
monoamines in the synaptic cleft, ultimately resulting in antidepressant
effects. Maprotiline and desipramine are relatively selective inhibitors of
norepinephrine reuptake.
– Blocking of receptors: TCAs also block serotonergic, α-adrenergic,
histaminic, and muscarinic receptors. It is not known if any of these
actions produce TCAs’ therapeutic benefit.
TRICYCLIC ANTIDEPRESSANTS (TCAs)
Pharmacological action:
• Central nervous system:
• ANS: Most TCAs are potent anticholinergics-cause dry mouth, blurring
of vision, constipation and urinary hesitancy as side effect.
Normal individual Depressed patient
It induces a peculiar clumsy
feeling, tiredness, light-
headedness, sleepiness, difficulty
in concentrating and thinking,
unsteady gait, anxiety.
no mood elevation or euphoria
Little acute effects are produced,
except sedation.
After 2-3 weeks of continuous
treatment, the mood is gradually
elevated, patients become more
communicative and start taking
interest in self and surroundings.
TRICYCLIC ANTIDEPRESSANTS (TCAs)
• CVS: Effects on cardiovascular function are prominent, occur at
therapeutic concentrations and may be dangerous in overdose.
– Tachycardia: due to anticholinergic and NA potentiating actions.
– Postural hypotension: due to inhibition of cardiovascular reflexes
and α1 blockade.
– ECG changes and cardiac arrhythmias: T wave suppression or
inversion is the most consistent change.
– Arrhythmias occur in overdose due to interference with
intraventricular conduction, combination of NA potentiating + ACh
blocking actions and direct myocardial depression.
TRICYCLIC ANTIDEPRESSANTS (TCAs)
Tolerance and dependence:
• Tolerance to the anticholinergic and hypotensive effects of
imipramine-like drugs develops gradually, though antidepressant
action is sustained.
• Psychological dependence on these drugs is rare, because their
acute effects are not pleasant.
• Acute poisoning:
• Poisoning with TCA is frequent and cause excitement, delirium,
and other anticholinergic symptoms as seen in atropine
poisoning.
• Treatment for acute TCA poisoning: Gastric lavage, respiratory
assistance, fluid infusion, maintenance of BP and body
temperature. Diazepam may be given i.c. to control convulsion
and delirium and to prevent cardiac arrhythmias, propranolol/
lidocaine may be used.
TRICYCLIC ANTIDEPRESSANTS (TCAs)
Pharmacokinetics:
• TCAs are well absorbed upon oral administration. Because of
their lipophilic nature, they are widely distributed and readily
penetrate into the CNS (t1/2 is 4 to 17 hours for imipramine).
• As a result of their variable first-pass metabolism in the liver,
dosage adjustment may require at the initial treatment period is
typically 4 to 8 weeks. The dosage can be gradually reduced to
improve tolerability, unless relapse occurs.
• These drugs are metabolized by the hepatic microsomal system
and conjugated with glucuronic acid. TCAs are excreted as
inactive metabolites via the kidney.
TRICYCLIC ANTIDEPRESSANTS (TCAs)
Adverse effects:
• Blockade of muscarinic receptors leads to blurred vision,
xerostomia (dry mouth), urinary retention, sinus tachycardia,
constipation, and aggravation of narrow-angle glaucoma.
• The TCAs also block α-adrenergic receptors, causing orthostatic
hypotension, dizziness, and reflex tachycardia.
• Weight gain is a common adverse effect of the TCAs. Sexual
dysfunction, as evidenced by erectile dysfunction in men and
anorgasmia in women, occurs in a significant minority of
patients, but the incidence is still considered to be lower than
the incidence of sexual dysfunction associated with the SSRIs.
Selective Serotonin Reuptake Inhibitors (SSRis)
The major limitations of conventional TCAs are:
• Frequent anticholinergic, cardiovascular and neurological side
effects.
• Relatively low safety margin, hazardous in overdose; fatalities
common.
• Lag time of 2-4 weeks before antidepressant action manifests.
• Significant number of patients respond incompletely and some
do not respond.
Selective Serotonin Reuptake Inhibitors (SSRis)
• The selective serotonin reuptake inhibitors (SSRIs) are inhibit
serotonin reuptake, having 300- to 3000-fold greater selectivity for
the serotonin transporter, as compared to the norepinephrine
transporter.
• SSRIs also have little blocking activity at muscarinic, α-adrenergic,
and histaminic H1 receptors.
• The SSRIs block the reuptake of serotonin,
leading to increased concentrations of the
neurotransmitter in the synaptic cleft and,
ultimately, to greater postsynaptic neuronal
activity.
• SSRIs, typically take at least 2 weeks to produce
significant improvement in mood, and maximum
benefit may require up to 12 weeks or more.
Selective Serotonin Reuptake Inhibitors (SSRis)
Pharmacokinetics
• All SSRI are well absorbed after oral administration.
• Food has little effect on absorption (except sertraline, for which
food will increase its absorption).
• Majority of SSRIs have plasma half –lives that range of 16-36 h.
• Metabolism by cytochrome P450 (CYP450)-dependent enzymes
and glucuronide or sulfate conjugation occur extensively.
• SSRIs may affect the metabolism of multiple medications and its
excretion of the SSRIs is primarily through the kidneys, except for
paroxetine and sertraline, which also undergo fecal excretion (35
and 50 percent, respectively).
• Dosages of all of these drugs should be adjusted downward in
patients with hepatic impairment.
Selective Serotonin Reuptake Inhibitors (SSRis)
Pharmacokinetics
• Fluoxetine differs from the other members of the class in two
respects. First, it has a longer half-life (50 hours) and is available
as a sustained-release preparation allowing once-weekly dosing.
• Second, the metabolite of the S-enantiomer, S-norfluoxetine, is
as potent as the parent compound. The half-life of the
metabolite is quite long, averaging 10 days.
• Fluoxetine and paroxetine are potent inhibitors of a hepatic
CYP450 isoenzyme (CYP2D6) responsible for the limination of
TCAs, neuroleptic drugs, and some antiarrhythmic and β-
adrenergic antagonist drugs. Other cytochrome enzymes
(CYP2C9/19, CYP3A4, CYP1A2) are involved with SSRI metabolism
and may also be inhibited to various degrees by the SSRIs.
Selective Serotonin Reuptake Inhibitors (SSRis)
Therapeutic uses
• The primary indication for SSRIs is depression, for which they are
as effective as the TCAs. A number of other psychiatric disorders
also respond favorably to SSRIs, including obsessive-compulsive
disorder, panic disorder, generalized anxiety disorder,
posttraumatic stress disorder, social anxiety disorder and
premenstrual dysphoric disorder.
• Fluoxetine is approved for Bulimia nervosa.
• Fluoxetine, sertraline, and fluvoxamine are approved for use in
children to treat obsessive-compulsive disorder, and fluoxetine is
approved to treat childhood depression by US-FDA.
Selective Serotonin Reuptake Inhibitors (SSRis)
Adverse effects
• SSRIs are considered to have fewer and less severe adverse
effects than the TCAs and MAOIs.
• SSRIs are commonly cause headache, sweating, anxiety and
agitation, gastrointestinal effects (nausea, vomiting, diarrhea),
weakness and fatigue, sexual dysfunction, changes in weight and
sleep disturbances (insomnia and somnolence).
• Sleep disturbances: Paroxetine and fluvoxamine are generally
more sedative than other SSRI. Can be used as antidepressant.
• Sexual dysfunction: Loss of libido, delayed ejaculation, and
anorgasmia are underreported side effects. In men with erectile
dysfunction and depression, treatment with sildenafil, vardenafil,
or tadalafil may improve sexual function.
Selective Serotonin Reuptake Inhibitors (SSRis)
Adverse effects
• Use in children and teenagers:
– Antidepressants should be used cautiously in children and
teenagers, because about 1 out of 50 children report suicidal
ideation as a result of SSRI treatment.
– Pediatric patients should be observed for worsening
depression and suicidal thinking whenever any antidepressant
is started or its dose is increased or decreased.
Selective Serotonin Reuptake Inhibitors (SSRis)
Overdoses:
• Large intakes of SSRIs do not cause cardiac arrhythmias
(compared to the arrhythmia risk for the TCAs), but seizures are a
possibility because all antidepressants may lower the seizure
threshold.
• All SSRIs have the potential to cause a serotonin syndrome that
may include the symptoms of hyperthermia, muscle rigidity,
sweating, myoclonus (clonic muscle twitching), and changes in
mental status and vital signs when used in the presence of a
MAOI or other highly serotonergic drug.
• Therefore, extended periods of washout for each drug class
should occur prior to the administration of the other class of
drugs.
Selective Serotonin Reuptake Inhibitors (SSRis)
Discontinuation syndrome:
• All SSRIs have the potential for causing a discontinuation
syndrome after their abrupt withdrawal, the agents with the
shorter half-lives and having inactive metabolites have a higher
risk for such an adverse reaction.
• Fluoxetine has the lowest risk of causing an SSRI
discontinuation syndrome.
• Possible signs and symptoms of such a serotonin-related
discontinuation syndrome include headache, malaise and flu-like
symptoms, agitation and irritability, nervousness, and changes in
sleep pattern.
Atypical antidepressants
Trazodone:
• It is the first atypical antidepressant; selectively but less
efficiently blocks 5-HT uptake and has prominent a blocking as
well as weak 5-HT2 antagonistic action.
• It is not anticholinergic, but causes bradycardia, and doesn't
interfere with intracardiac conduction, hence it is less prone to
cause arrhythmia.
• trazodone is well tolerated and relatively safe in overdose:
seizures do not occur. Its t1/z is short (approx. 6 hr).
• ADR: Inappropriate, prolonged and painful penile erection
(priapism) occurs in few recipients resulting in impotence.
Atypical antidepressants
Mianserin • not inhibiting either NA or 5-HT uptake;
but blocks presynaptic alpha 2 receptors
Tianeptine • This antidepressant is reported to
increase rather than inhibit 5-HT uptake,
and is neither sedative nor stimulant.
Amineptine • Enhances 5-HT uptake
• It produces anticholinergic side effects
including tachycardia, confusion and
delirium.
• Postural hypotension, conduction
disturbances and arrhythmias can occur,
especially in patients with heart disease.
Venlafaxine • A novel antidepressant referred to as
'serotonin and noradrenaline reuptake
inhibitor' (SNRI)
Atypical antidepressants
USES
• Endogenous (major) depression
• Obsessive-compulsive and phobic status
• Anxiety disorders
• Neuropathic pain
• Attention deficit-hyperactivity disorder in children
• Enuresis
• Migraine
• Pruritus
Thank you

More Related Content

What's hot (20)

Antiparkinsonian drugs - drdhriti
Antiparkinsonian drugs - drdhritiAntiparkinsonian drugs - drdhriti
Antiparkinsonian drugs - drdhriti
 
Antidepressant drugs
Antidepressant drugsAntidepressant drugs
Antidepressant drugs
 
Anti depressant and its classifications
Anti depressant and its classificationsAnti depressant and its classifications
Anti depressant and its classifications
 
Antidepressants -pharmacology
Antidepressants -pharmacologyAntidepressants -pharmacology
Antidepressants -pharmacology
 
Anti parkinsonian drugs
Anti parkinsonian drugsAnti parkinsonian drugs
Anti parkinsonian drugs
 
Antipsychotic drugs
Antipsychotic drugsAntipsychotic drugs
Antipsychotic drugs
 
Antidepressants Pharmacology
Antidepressants  PharmacologyAntidepressants  Pharmacology
Antidepressants Pharmacology
 
Antipsychotic drugs
Antipsychotic drugsAntipsychotic drugs
Antipsychotic drugs
 
Benzodiazepines
BenzodiazepinesBenzodiazepines
Benzodiazepines
 
Sedatives & hypnotics
Sedatives & hypnoticsSedatives & hypnotics
Sedatives & hypnotics
 
Anticonvulsants
AnticonvulsantsAnticonvulsants
Anticonvulsants
 
Antidepressant drugs
Antidepressant drugsAntidepressant drugs
Antidepressant drugs
 
Pharmacology of dopamine
Pharmacology of dopaminePharmacology of dopamine
Pharmacology of dopamine
 
Monoamine Oxidase Inhibitors (MAOIs)
Monoamine Oxidase Inhibitors (MAOIs)Monoamine Oxidase Inhibitors (MAOIs)
Monoamine Oxidase Inhibitors (MAOIs)
 
ANTIDEPRESSANTS
ANTIDEPRESSANTSANTIDEPRESSANTS
ANTIDEPRESSANTS
 
Antiepileptics (New) - drdhriti
Antiepileptics (New) - drdhritiAntiepileptics (New) - drdhriti
Antiepileptics (New) - drdhriti
 
Mood Stabilisers (Antimanic drugs)
Mood Stabilisers (Antimanic drugs)Mood Stabilisers (Antimanic drugs)
Mood Stabilisers (Antimanic drugs)
 
Antidepressants
AntidepressantsAntidepressants
Antidepressants
 
Sedative Hypnotic
Sedative HypnoticSedative Hypnotic
Sedative Hypnotic
 
Pharmacology of Antiepileptic Drugs
Pharmacology of Antiepileptic DrugsPharmacology of Antiepileptic Drugs
Pharmacology of Antiepileptic Drugs
 

Viewers also liked

Antidepressants powerpoint
Antidepressants powerpointAntidepressants powerpoint
Antidepressants powerpointAllegra Lange
 
Antidepressents Med Chem Lecture
Antidepressents Med Chem LectureAntidepressents Med Chem Lecture
Antidepressents Med Chem Lecturesagar joshi
 
Anti -depressants: classification & mechanism of action
Anti -depressants: classification & mechanism of actionAnti -depressants: classification & mechanism of action
Anti -depressants: classification & mechanism of actionDr. Kanishk Sharma
 
Primox (Generic Nortriptyline Hydrochloride Tablets)
Primox (Generic Nortriptyline Hydrochloride Tablets) Primox (Generic Nortriptyline Hydrochloride Tablets)
Primox (Generic Nortriptyline Hydrochloride Tablets) Clearsky Pharmacy
 
Análisis de Subgéneros
Análisis de SubgénerosAnálisis de Subgéneros
Análisis de SubgénerosMIRNUS
 
Мы - за ЗДОРОВЫЙ ОБРАЗ ЖИЗНИ!
Мы - за ЗДОРОВЫЙ ОБРАЗ ЖИЗНИ!Мы - за ЗДОРОВЫЙ ОБРАЗ ЖИЗНИ!
Мы - за ЗДОРОВЫЙ ОБРАЗ ЖИЗНИ!ander_temp
 
Έχω και εγώ δικαίωμα
Έχω και εγώ δικαίωμαΈχω και εγώ δικαίωμα
Έχω και εγώ δικαίωμα14Dimotiko
 
Adeus celulite com folia
Adeus celulite com foliaAdeus celulite com folia
Adeus celulite com foliaFolia
 
புகை பிடித்தல் ஏற்படும் தீமைகள்
புகை பிடித்தல் ஏற்படும் தீமைகள்புகை பிடித்தல் ஏற்படும் தீமைகள்
புகை பிடித்தல் ஏற்படும் தீமைகள்Subramani Parasuraman
 
Antidepressants Part I
Antidepressants Part IAntidepressants Part I
Antidepressants Part IBrian Piper
 
Diabetes gestacional pwp final
Diabetes gestacional  pwp finalDiabetes gestacional  pwp final
Diabetes gestacional pwp finalVanesa Miana
 
Transportation & Car Business in USA, Nov 10, 2015
Transportation & Car Business in USA, Nov 10, 2015Transportation & Car Business in USA, Nov 10, 2015
Transportation & Car Business in USA, Nov 10, 2015Business Finland
 

Viewers also liked (20)

Antidepressants powerpoint
Antidepressants powerpointAntidepressants powerpoint
Antidepressants powerpoint
 
Antidepressants
Antidepressants Antidepressants
Antidepressants
 
Anti depressants
Anti depressantsAnti depressants
Anti depressants
 
Antidepressants
AntidepressantsAntidepressants
Antidepressants
 
Antidepressants
AntidepressantsAntidepressants
Antidepressants
 
Antidepressents Med Chem Lecture
Antidepressents Med Chem LectureAntidepressents Med Chem Lecture
Antidepressents Med Chem Lecture
 
Anti Depressing Drugs
Anti Depressing DrugsAnti Depressing Drugs
Anti Depressing Drugs
 
Anti -depressants: classification & mechanism of action
Anti -depressants: classification & mechanism of actionAnti -depressants: classification & mechanism of action
Anti -depressants: classification & mechanism of action
 
TCAS
TCASTCAS
TCAS
 
Primox (Generic Nortriptyline Hydrochloride Tablets)
Primox (Generic Nortriptyline Hydrochloride Tablets) Primox (Generic Nortriptyline Hydrochloride Tablets)
Primox (Generic Nortriptyline Hydrochloride Tablets)
 
Análisis de Subgéneros
Análisis de SubgénerosAnálisis de Subgéneros
Análisis de Subgéneros
 
Sangre
SangreSangre
Sangre
 
Мы - за ЗДОРОВЫЙ ОБРАЗ ЖИЗНИ!
Мы - за ЗДОРОВЫЙ ОБРАЗ ЖИЗНИ!Мы - за ЗДОРОВЫЙ ОБРАЗ ЖИЗНИ!
Мы - за ЗДОРОВЫЙ ОБРАЗ ЖИЗНИ!
 
Έχω και εγώ δικαίωμα
Έχω και εγώ δικαίωμαΈχω και εγώ δικαίωμα
Έχω και εγώ δικαίωμα
 
Adeus celulite com folia
Adeus celulite com foliaAdeus celulite com folia
Adeus celulite com folia
 
புகை பிடித்தல் ஏற்படும் தீமைகள்
புகை பிடித்தல் ஏற்படும் தீமைகள்புகை பிடித்தல் ஏற்படும் தீமைகள்
புகை பிடித்தல் ஏற்படும் தீமைகள்
 
Antidepressants Part I
Antidepressants Part IAntidepressants Part I
Antidepressants Part I
 
Diabetes gestacional pwp final
Diabetes gestacional  pwp finalDiabetes gestacional  pwp final
Diabetes gestacional pwp final
 
Transportation & Car Business in USA, Nov 10, 2015
Transportation & Car Business in USA, Nov 10, 2015Transportation & Car Business in USA, Nov 10, 2015
Transportation & Car Business in USA, Nov 10, 2015
 
Epidemiological statistics II
Epidemiological statistics IIEpidemiological statistics II
Epidemiological statistics II
 

Similar to Antidepressants

Mahi anti depressants
Mahi anti depressantsMahi anti depressants
Mahi anti depressantsMahi Yeruva
 
antidepressants-tcassri-090907232222-phpapp02.pptx
antidepressants-tcassri-090907232222-phpapp02.pptxantidepressants-tcassri-090907232222-phpapp02.pptx
antidepressants-tcassri-090907232222-phpapp02.pptxHungryHostellite
 
antidepressants-210723100900.pdf
antidepressants-210723100900.pdfantidepressants-210723100900.pdf
antidepressants-210723100900.pdfChintuCH1
 
Basic Pharmacology of Antidepressants.ppt
Basic Pharmacology of Antidepressants.pptBasic Pharmacology of Antidepressants.ppt
Basic Pharmacology of Antidepressants.pptNorhanKhaled15
 
Antidepressant pharmacology
Antidepressant pharmacology Antidepressant pharmacology
Antidepressant pharmacology Ahmed Morgan
 
Antidepressants. Mood Stabilizers. Psychostimulants
Antidepressants. Mood Stabilizers. PsychostimulantsAntidepressants. Mood Stabilizers. Psychostimulants
Antidepressants. Mood Stabilizers. PsychostimulantsEneutron
 
antidepressant drugs.pptx
antidepressant drugs.pptxantidepressant drugs.pptx
antidepressant drugs.pptxZORAIZ HAIDER
 
Anti depressants (1)
Anti depressants (1)Anti depressants (1)
Anti depressants (1)Zainab&Sons
 
Antidepressants BY Dise.pptx
Antidepressants BY Dise.pptxAntidepressants BY Dise.pptx
Antidepressants BY Dise.pptxXavier875943
 
Anti-depressant drugs ( pharmacology-III)
Anti-depressant drugs ( pharmacology-III)Anti-depressant drugs ( pharmacology-III)
Anti-depressant drugs ( pharmacology-III)MdIrfanUddin2
 
CNS - disorders , symptoms and treatment
CNS - disorders , symptoms and treatment CNS - disorders , symptoms and treatment
CNS - disorders , symptoms and treatment Areej Abu Hanieh
 
Drugs for Affective Disorders
Drugs for Affective DisordersDrugs for Affective Disorders
Drugs for Affective DisordersRAJESHWAR CHAVAN
 
Antidepressants. CNS stimulants.pdf
Antidepressants. CNS stimulants.pdfAntidepressants. CNS stimulants.pdf
Antidepressants. CNS stimulants.pdfHUMAIDKHAN5
 

Similar to Antidepressants (20)

Depression
DepressionDepression
Depression
 
ANTIDEPRESSANTS.pptx
ANTIDEPRESSANTS.pptxANTIDEPRESSANTS.pptx
ANTIDEPRESSANTS.pptx
 
Antidepressants.pptx
Antidepressants.pptxAntidepressants.pptx
Antidepressants.pptx
 
Mahi anti depressants
Mahi anti depressantsMahi anti depressants
Mahi anti depressants
 
Antidepressants Tca Ssri
Antidepressants   Tca SsriAntidepressants   Tca Ssri
Antidepressants Tca Ssri
 
antidepressants-tcassri-090907232222-phpapp02.pptx
antidepressants-tcassri-090907232222-phpapp02.pptxantidepressants-tcassri-090907232222-phpapp02.pptx
antidepressants-tcassri-090907232222-phpapp02.pptx
 
antidepressants-210723100900.pdf
antidepressants-210723100900.pdfantidepressants-210723100900.pdf
antidepressants-210723100900.pdf
 
Basic Pharmacology of Antidepressants.ppt
Basic Pharmacology of Antidepressants.pptBasic Pharmacology of Antidepressants.ppt
Basic Pharmacology of Antidepressants.ppt
 
Antidepressant pharmacology
Antidepressant pharmacology Antidepressant pharmacology
Antidepressant pharmacology
 
Antidepressants. Mood Stabilizers. Psychostimulants
Antidepressants. Mood Stabilizers. PsychostimulantsAntidepressants. Mood Stabilizers. Psychostimulants
Antidepressants. Mood Stabilizers. Psychostimulants
 
Antidepressants
AntidepressantsAntidepressants
Antidepressants
 
antidepressant drugs.pptx
antidepressant drugs.pptxantidepressant drugs.pptx
antidepressant drugs.pptx
 
Anti depressants (1)
Anti depressants (1)Anti depressants (1)
Anti depressants (1)
 
Antidepressants BY Dise.pptx
Antidepressants BY Dise.pptxAntidepressants BY Dise.pptx
Antidepressants BY Dise.pptx
 
Anti-depressant drugs ( pharmacology-III)
Anti-depressant drugs ( pharmacology-III)Anti-depressant drugs ( pharmacology-III)
Anti-depressant drugs ( pharmacology-III)
 
Antidepressants ppt final
Antidepressants  ppt finalAntidepressants  ppt final
Antidepressants ppt final
 
CNS - disorders , symptoms and treatment
CNS - disorders , symptoms and treatment CNS - disorders , symptoms and treatment
CNS - disorders , symptoms and treatment
 
Antidepressants
AntidepressantsAntidepressants
Antidepressants
 
Drugs for Affective Disorders
Drugs for Affective DisordersDrugs for Affective Disorders
Drugs for Affective Disorders
 
Antidepressants. CNS stimulants.pdf
Antidepressants. CNS stimulants.pdfAntidepressants. CNS stimulants.pdf
Antidepressants. CNS stimulants.pdf
 

More from Subramani Parasuraman

More from Subramani Parasuraman (20)

Research with animals and animal models.pptx
Research with animals and animal models.pptxResearch with animals and animal models.pptx
Research with animals and animal models.pptx
 
Nicotine and Tobacco
Nicotine and TobaccoNicotine and Tobacco
Nicotine and Tobacco
 
Statistical software.pptx
Statistical software.pptxStatistical software.pptx
Statistical software.pptx
 
Cerebellum and control of postures and movements.pptx
Cerebellum and control of postures and movements.pptxCerebellum and control of postures and movements.pptx
Cerebellum and control of postures and movements.pptx
 
Drugs Used in Renal Alteration
Drugs Used in Renal AlterationDrugs Used in Renal Alteration
Drugs Used in Renal Alteration
 
Drugs Used in Endocrine Alteration
Drugs Used in Endocrine AlterationDrugs Used in Endocrine Alteration
Drugs Used in Endocrine Alteration
 
Antidiabetic drugs
Antidiabetic drugsAntidiabetic drugs
Antidiabetic drugs
 
Pancreatic Hormones
Pancreatic HormonesPancreatic Hormones
Pancreatic Hormones
 
Terrestrial laboratory animals
Terrestrial laboratory animalsTerrestrial laboratory animals
Terrestrial laboratory animals
 
Drugs used in haematological disorders
Drugs used in haematological disordersDrugs used in haematological disorders
Drugs used in haematological disorders
 
Laboratory animals
Laboratory animalsLaboratory animals
Laboratory animals
 
Immunomodulators-1.pptx
Immunomodulators-1.pptxImmunomodulators-1.pptx
Immunomodulators-1.pptx
 
Immunomodulators - 3.pptx
Immunomodulators - 3.pptxImmunomodulators - 3.pptx
Immunomodulators - 3.pptx
 
Immunomodulators - 2.pptx
Immunomodulators - 2.pptxImmunomodulators - 2.pptx
Immunomodulators - 2.pptx
 
Acetylcholine bioassay
 Acetylcholine bioassay Acetylcholine bioassay
Acetylcholine bioassay
 
Oxytocin bioassay
Oxytocin bioassayOxytocin bioassay
Oxytocin bioassay
 
Type of bioassays
Type of bioassaysType of bioassays
Type of bioassays
 
Principles of bioassay
Principles of bioassayPrinciples of bioassay
Principles of bioassay
 
PK - Excretion.pptx
PK - Excretion.pptxPK - Excretion.pptx
PK - Excretion.pptx
 
Absorption
AbsorptionAbsorption
Absorption
 

Recently uploaded

How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17Celine George
 
AUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptxAUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptxiammrhaywood
 
In - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxIn - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxAditiChauhan701637
 
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxPractical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxKatherine Villaluna
 
Patterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxPatterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxMYDA ANGELICA SUAN
 
What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?TechSoup
 
How to Solve Singleton Error in the Odoo 17
How to Solve Singleton Error in the  Odoo 17How to Solve Singleton Error in the  Odoo 17
How to Solve Singleton Error in the Odoo 17Celine George
 
Education and training program in the hospital APR.pptx
Education and training program in the hospital APR.pptxEducation and training program in the hospital APR.pptx
Education and training program in the hospital APR.pptxraviapr7
 
How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17Celine George
 
Benefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationBenefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationMJDuyan
 
CAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptxCAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptxSaurabhParmar42
 
Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.raviapr7
 
How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17Celine George
 
Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.EnglishCEIPdeSigeiro
 
HED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfHED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfMohonDas
 
M-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptxM-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptxDr. Santhosh Kumar. N
 
How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17Celine George
 
5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...CaraSkikne1
 
3.21.24 The Origins of Black Power.pptx
3.21.24  The Origins of Black Power.pptx3.21.24  The Origins of Black Power.pptx
3.21.24 The Origins of Black Power.pptxmary850239
 

Recently uploaded (20)

How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17
 
AUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptxAUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptx
 
In - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxIn - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptx
 
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxPractical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
 
Patterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxPatterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptx
 
What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?
 
How to Solve Singleton Error in the Odoo 17
How to Solve Singleton Error in the  Odoo 17How to Solve Singleton Error in the  Odoo 17
How to Solve Singleton Error in the Odoo 17
 
Education and training program in the hospital APR.pptx
Education and training program in the hospital APR.pptxEducation and training program in the hospital APR.pptx
Education and training program in the hospital APR.pptx
 
How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17
 
Benefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationBenefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive Education
 
CAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptxCAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptx
 
Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.
 
Finals of Kant get Marx 2.0 : a general politics quiz
Finals of Kant get Marx 2.0 : a general politics quizFinals of Kant get Marx 2.0 : a general politics quiz
Finals of Kant get Marx 2.0 : a general politics quiz
 
How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17
 
Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.
 
HED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfHED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdf
 
M-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptxM-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptx
 
How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17
 
5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...
 
3.21.24 The Origins of Black Power.pptx
3.21.24  The Origins of Black Power.pptx3.21.24  The Origins of Black Power.pptx
3.21.24 The Origins of Black Power.pptx
 

Antidepressants

  • 1. Antidepressants Dr. S. Parasuraman M.Pharm., Ph.D., Senior Lecturer, Faculty of Pharmacy, AIMST University, Bedong 08100, Malaysia.
  • 2. Depression • Major depression and mania are two extremes of affective disorders which refer to a pathological change in mood state. • The symptoms of depression are intense feelings of sadness, hopelessness, and despair as well as the inability to experience pleasure in usual activities, changes in sleep patterns and appetite, loss of energy, and suicidal thoughts. Mania is characterized by the opposite behavior: enthusiasm, rapid thought and speech patterns, extreme self-confidence, and impaired judgment.
  • 3. Classification of anti-depresent • Reversible inhibitors of MAO-A (RIMAs): Moclobemide, Clorgyline • Tricyclic antidepressants (TCAs): – NA + 5-HT reuptake inhibitors: Imipramine, Amitriptyline, Trimipramine, Doxepin, Dothiepin, Clomipramine – Predominantly NA reuptake inhibitors: Desipramine, Nortriptyline, Amoxapine, Reboxetine • Selective serotonin reuptake inhibitors (SSRis): Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Citalopram, Escitalopram • Atypical antidepressants: Trazodone, Mianserin, Mirtazapine, Venlafaxine, Duloxetine, Tianeptine, Amineptine, Bupropion • 5-HT2Antagonists: trazodone and nefazodone
  • 4. • AC, adenylyl cyclase; • 5-HT, serotonin; • CREB, cAMP response element- binding (protein); • DAG, diacyl glycerol; • IP3, inositol trisphosphate; • MAO, monoamine oxidase; • NET, norepinephrine transporter; • PKC, protein kinase C; • PLC, phospholipase Depression
  • 5. Hypothesis of major depression • Depression appears to be associated with changes in serotonin or norepinephrine signaling in the brain (or both) with significant downstream effects. • Most antidepressants cause changes in amine signaling.
  • 6. MAO inhibitors • MAO is a mitochondrial enzyme involved in the oxidative deamination of biogenic amines (Adr, NA, DA, 5-HT). Two isoenzyme forms of MAO have been identified. • Dopamine is degraded equally by both isoenzymes. • MOA inhibitors inhibits the metabolism of biological amines to cause disproportionate elevation of mood. MOA isoenzymes Active against Inhibited by MAO-A 5-HT and NA Clorgyline, Moclobemide MAO-B Phenylethylamine Selegiline
  • 7. MAO inhibitors • The nonselective MAO inhibitors causes – elevate the mood in depressed patients – progress to hypomania and mania – excitement and hypomania may be produced in nondepressed individuals • The drugs themselves stay in the body for relatively short periods, but their effects last for 2-3 weeks after discontinuation. • MOA inhibitors are 'hit and run' drugs-return of MAO activity depends on synthesis of fresh enzyme; tissue monoamine levels remain elevated long after the drug has been largely eliminated.
  • 8. MAO inhibitors • Interactions: MAO inhibitors inhibits a number of other enzymes as well, and interact with many food constituents and drugs. – Cheese reaction: MAO inhibiters indirectly acting sympathomimetic amines escape degradation in intestinal wall and liver  reaching into systemic circulation they displace large amounts of NA from transmitter loaded adrenergic nerve endings  hypertensive crisis, cerebrovascular accidents. Alpha blockers (e.g.: phentolamine, prazosin) or chlorpromazine can be used for treatment of chees reaction. – Cold and cough remedies: Cough syrup contains ephedrine or other sympathomimetics  cause hypertensive reaction. – Reserpine, guanethidine, tricyclic antidepressants: Excitement, rice in BP and body temperature can occur when given these drugs to patient on MOA inhibitor (due to NA release or uptake blocking action).
  • 9. MAO inhibitors – Levodopa: Excitement and hypertension, due to increase in biological half life of DA and NA. – Antiparkinsonian anticholinergics: Hallucinations and symptoms similar to those of atropine poisoning occur. – Barbiturates, alcohol, opioids, antihistamines: respiration may fail. – Pethidine: High fever, sweating, excitation, delirium, convulsions, and severe respiratory depression may occur.
  • 10. Reversible inhibitors of MAO-A Moclobemide • It is reversible and selective MAO-A inhibitor with short duration of action and full MAO activity is restored within 1-2 days of stopping the drug. • Its effective antidepressant, comparable to TCAs. • It lacks the anticholinergic, sedative, cognitive, psychomotor and cardiovascular adverse effects of typical TCAs and is safer in overdose. • ADR: nausea, dizziness, headache, insomnia, rarely excitement and liver damage. • Use: Alternative for TCAs for mild to moderate depression and social phobia. • Dose: 150 mg; BD or TID (Max 600 mg/ kg/ day)
  • 11. TRICYCLIC ANTIDEPRESSANTS (TCAs) Imipramine • It is an analogue of CPZ and found during clinical trails to selectively benefit depressed but not agitated psychotics. • MOA: – TCAs block norepinephrine and serotonin reuptake into the neuron. – Inhibition of neurotransmitter reuptake: TCAs is potent inhibitors of the neuronal reuptake of norepinephrine and serotonin into presynaptic nerve terminals. At therapeutic concentrations, they do not block dopamine transporters. TCAs cause increased concentrations of monoamines in the synaptic cleft, ultimately resulting in antidepressant effects. Maprotiline and desipramine are relatively selective inhibitors of norepinephrine reuptake. – Blocking of receptors: TCAs also block serotonergic, α-adrenergic, histaminic, and muscarinic receptors. It is not known if any of these actions produce TCAs’ therapeutic benefit.
  • 12. TRICYCLIC ANTIDEPRESSANTS (TCAs) Pharmacological action: • Central nervous system: • ANS: Most TCAs are potent anticholinergics-cause dry mouth, blurring of vision, constipation and urinary hesitancy as side effect. Normal individual Depressed patient It induces a peculiar clumsy feeling, tiredness, light- headedness, sleepiness, difficulty in concentrating and thinking, unsteady gait, anxiety. no mood elevation or euphoria Little acute effects are produced, except sedation. After 2-3 weeks of continuous treatment, the mood is gradually elevated, patients become more communicative and start taking interest in self and surroundings.
  • 13. TRICYCLIC ANTIDEPRESSANTS (TCAs) • CVS: Effects on cardiovascular function are prominent, occur at therapeutic concentrations and may be dangerous in overdose. – Tachycardia: due to anticholinergic and NA potentiating actions. – Postural hypotension: due to inhibition of cardiovascular reflexes and α1 blockade. – ECG changes and cardiac arrhythmias: T wave suppression or inversion is the most consistent change. – Arrhythmias occur in overdose due to interference with intraventricular conduction, combination of NA potentiating + ACh blocking actions and direct myocardial depression.
  • 14. TRICYCLIC ANTIDEPRESSANTS (TCAs) Tolerance and dependence: • Tolerance to the anticholinergic and hypotensive effects of imipramine-like drugs develops gradually, though antidepressant action is sustained. • Psychological dependence on these drugs is rare, because their acute effects are not pleasant. • Acute poisoning: • Poisoning with TCA is frequent and cause excitement, delirium, and other anticholinergic symptoms as seen in atropine poisoning. • Treatment for acute TCA poisoning: Gastric lavage, respiratory assistance, fluid infusion, maintenance of BP and body temperature. Diazepam may be given i.c. to control convulsion and delirium and to prevent cardiac arrhythmias, propranolol/ lidocaine may be used.
  • 15. TRICYCLIC ANTIDEPRESSANTS (TCAs) Pharmacokinetics: • TCAs are well absorbed upon oral administration. Because of their lipophilic nature, they are widely distributed and readily penetrate into the CNS (t1/2 is 4 to 17 hours for imipramine). • As a result of their variable first-pass metabolism in the liver, dosage adjustment may require at the initial treatment period is typically 4 to 8 weeks. The dosage can be gradually reduced to improve tolerability, unless relapse occurs. • These drugs are metabolized by the hepatic microsomal system and conjugated with glucuronic acid. TCAs are excreted as inactive metabolites via the kidney.
  • 16. TRICYCLIC ANTIDEPRESSANTS (TCAs) Adverse effects: • Blockade of muscarinic receptors leads to blurred vision, xerostomia (dry mouth), urinary retention, sinus tachycardia, constipation, and aggravation of narrow-angle glaucoma. • The TCAs also block α-adrenergic receptors, causing orthostatic hypotension, dizziness, and reflex tachycardia. • Weight gain is a common adverse effect of the TCAs. Sexual dysfunction, as evidenced by erectile dysfunction in men and anorgasmia in women, occurs in a significant minority of patients, but the incidence is still considered to be lower than the incidence of sexual dysfunction associated with the SSRIs.
  • 17. Selective Serotonin Reuptake Inhibitors (SSRis) The major limitations of conventional TCAs are: • Frequent anticholinergic, cardiovascular and neurological side effects. • Relatively low safety margin, hazardous in overdose; fatalities common. • Lag time of 2-4 weeks before antidepressant action manifests. • Significant number of patients respond incompletely and some do not respond.
  • 18. Selective Serotonin Reuptake Inhibitors (SSRis) • The selective serotonin reuptake inhibitors (SSRIs) are inhibit serotonin reuptake, having 300- to 3000-fold greater selectivity for the serotonin transporter, as compared to the norepinephrine transporter. • SSRIs also have little blocking activity at muscarinic, α-adrenergic, and histaminic H1 receptors. • The SSRIs block the reuptake of serotonin, leading to increased concentrations of the neurotransmitter in the synaptic cleft and, ultimately, to greater postsynaptic neuronal activity. • SSRIs, typically take at least 2 weeks to produce significant improvement in mood, and maximum benefit may require up to 12 weeks or more.
  • 19. Selective Serotonin Reuptake Inhibitors (SSRis) Pharmacokinetics • All SSRI are well absorbed after oral administration. • Food has little effect on absorption (except sertraline, for which food will increase its absorption). • Majority of SSRIs have plasma half –lives that range of 16-36 h. • Metabolism by cytochrome P450 (CYP450)-dependent enzymes and glucuronide or sulfate conjugation occur extensively. • SSRIs may affect the metabolism of multiple medications and its excretion of the SSRIs is primarily through the kidneys, except for paroxetine and sertraline, which also undergo fecal excretion (35 and 50 percent, respectively). • Dosages of all of these drugs should be adjusted downward in patients with hepatic impairment.
  • 20. Selective Serotonin Reuptake Inhibitors (SSRis) Pharmacokinetics • Fluoxetine differs from the other members of the class in two respects. First, it has a longer half-life (50 hours) and is available as a sustained-release preparation allowing once-weekly dosing. • Second, the metabolite of the S-enantiomer, S-norfluoxetine, is as potent as the parent compound. The half-life of the metabolite is quite long, averaging 10 days. • Fluoxetine and paroxetine are potent inhibitors of a hepatic CYP450 isoenzyme (CYP2D6) responsible for the limination of TCAs, neuroleptic drugs, and some antiarrhythmic and β- adrenergic antagonist drugs. Other cytochrome enzymes (CYP2C9/19, CYP3A4, CYP1A2) are involved with SSRI metabolism and may also be inhibited to various degrees by the SSRIs.
  • 21. Selective Serotonin Reuptake Inhibitors (SSRis) Therapeutic uses • The primary indication for SSRIs is depression, for which they are as effective as the TCAs. A number of other psychiatric disorders also respond favorably to SSRIs, including obsessive-compulsive disorder, panic disorder, generalized anxiety disorder, posttraumatic stress disorder, social anxiety disorder and premenstrual dysphoric disorder. • Fluoxetine is approved for Bulimia nervosa. • Fluoxetine, sertraline, and fluvoxamine are approved for use in children to treat obsessive-compulsive disorder, and fluoxetine is approved to treat childhood depression by US-FDA.
  • 22. Selective Serotonin Reuptake Inhibitors (SSRis) Adverse effects • SSRIs are considered to have fewer and less severe adverse effects than the TCAs and MAOIs. • SSRIs are commonly cause headache, sweating, anxiety and agitation, gastrointestinal effects (nausea, vomiting, diarrhea), weakness and fatigue, sexual dysfunction, changes in weight and sleep disturbances (insomnia and somnolence). • Sleep disturbances: Paroxetine and fluvoxamine are generally more sedative than other SSRI. Can be used as antidepressant. • Sexual dysfunction: Loss of libido, delayed ejaculation, and anorgasmia are underreported side effects. In men with erectile dysfunction and depression, treatment with sildenafil, vardenafil, or tadalafil may improve sexual function.
  • 23. Selective Serotonin Reuptake Inhibitors (SSRis) Adverse effects • Use in children and teenagers: – Antidepressants should be used cautiously in children and teenagers, because about 1 out of 50 children report suicidal ideation as a result of SSRI treatment. – Pediatric patients should be observed for worsening depression and suicidal thinking whenever any antidepressant is started or its dose is increased or decreased.
  • 24. Selective Serotonin Reuptake Inhibitors (SSRis) Overdoses: • Large intakes of SSRIs do not cause cardiac arrhythmias (compared to the arrhythmia risk for the TCAs), but seizures are a possibility because all antidepressants may lower the seizure threshold. • All SSRIs have the potential to cause a serotonin syndrome that may include the symptoms of hyperthermia, muscle rigidity, sweating, myoclonus (clonic muscle twitching), and changes in mental status and vital signs when used in the presence of a MAOI or other highly serotonergic drug. • Therefore, extended periods of washout for each drug class should occur prior to the administration of the other class of drugs.
  • 25. Selective Serotonin Reuptake Inhibitors (SSRis) Discontinuation syndrome: • All SSRIs have the potential for causing a discontinuation syndrome after their abrupt withdrawal, the agents with the shorter half-lives and having inactive metabolites have a higher risk for such an adverse reaction. • Fluoxetine has the lowest risk of causing an SSRI discontinuation syndrome. • Possible signs and symptoms of such a serotonin-related discontinuation syndrome include headache, malaise and flu-like symptoms, agitation and irritability, nervousness, and changes in sleep pattern.
  • 26. Atypical antidepressants Trazodone: • It is the first atypical antidepressant; selectively but less efficiently blocks 5-HT uptake and has prominent a blocking as well as weak 5-HT2 antagonistic action. • It is not anticholinergic, but causes bradycardia, and doesn't interfere with intracardiac conduction, hence it is less prone to cause arrhythmia. • trazodone is well tolerated and relatively safe in overdose: seizures do not occur. Its t1/z is short (approx. 6 hr). • ADR: Inappropriate, prolonged and painful penile erection (priapism) occurs in few recipients resulting in impotence.
  • 27. Atypical antidepressants Mianserin • not inhibiting either NA or 5-HT uptake; but blocks presynaptic alpha 2 receptors Tianeptine • This antidepressant is reported to increase rather than inhibit 5-HT uptake, and is neither sedative nor stimulant. Amineptine • Enhances 5-HT uptake • It produces anticholinergic side effects including tachycardia, confusion and delirium. • Postural hypotension, conduction disturbances and arrhythmias can occur, especially in patients with heart disease. Venlafaxine • A novel antidepressant referred to as 'serotonin and noradrenaline reuptake inhibitor' (SNRI)
  • 28. Atypical antidepressants USES • Endogenous (major) depression • Obsessive-compulsive and phobic status • Anxiety disorders • Neuropathic pain • Attention deficit-hyperactivity disorder in children • Enuresis • Migraine • Pruritus